Category Filter
- Advanced Imaging
- Autism Spectrum Mandate
- Behavioral Health
- Blue Advantage Policies
- Chronic Condition Management
- Genetic Testing
- HelpScript Program
- Hemophilia Drugs
- Medical Policies
- Pre-Service Review (Predetermination/Precertification)
- Provider-Administered Drug Policies
- Radiation Therapy
- Self-Administered Drug Policies
- Transgender Services
Asset Publisher
Copay Waiver for Breast Cancer Primary Prevention Agent ACA Copay Waiver Program Summary – Individual Marketplace, Commercial
Policy Number: PH-1088
This program is implemented without the sex edit.
This program applies to Blue Partner, Commercial, GenPlus, NetResults A series, SourceRx and Health Insurance Marketplace formularies.
CLINICAL RATIONALE
The Affordable Care Act (ACA) requires a member-friendly mechanism for waiving the cost share for an alternative recommended product deemed medically necessary by the provider when a health care provider considers the $0 covered product is inappropriate for an individual. Prime Therapeutics offers a standard coverage exception/cost share waiver policy that is applied across all ACA categories.
https://www.cms.gov/CCIIO/Resources/Fact-Sheets-and-FAQs/aca_implementation_faqs12.html
https://www.cms.gov/CCIIO/Resources/Fact-Sheets-and-FAQs/Downloads/aca_implementation_faqs26.pdf
Breast Cancer Primary Prevention Agent ACA Copay Waiver Criteria
OBJECTIVE
The intent of the ACA Prevention Copay Waiver Criteria is to help ensure the copay waiver, when applicable based on the member’s benefit, is applied to the appropriate population as described by the United States Preventative Services Task Force (USPSTF).
CRITERIA FOR APPROVAL
The requested breast cancer primary prevention agent will be approved when ALL of the following are met:
- The requested breast cancer primary prevention agent is covered under the pharmacy benefit or has been approved through the coverage exception process
AND
- The prescriber has provided information stating that the requested breast cancer primary prevention agent is medically necessary
AND
- The requested agent is tamoxifen, raloxifene, or aromatase inhibitor (anastrozole, exemestane, letrozole)
AND
- The patient is 35 years of age or over
AND
- The agent is requested for the primary prevention of breast cancer
AND
- ONE of the following:
- The plan has not implemented a sex requirement
OR
- The plan has implemented a sex requirement AND ONE of the following:
- The patient’s sex is female
OR
-
- The prescriber has provided information that the requested agent is medically appropriate for the patient’s sex
Length of Approval: 12 months
This pharmacy policy is not an authorization, certification, explanation of benefits or a contract. Eligibility and benefits are determined on a case-by-case basis according to the terms of the member’s plan in effect as of the date services are rendered. All pharmacy policies are based on (i) information in FDA approved package inserts (and black box warning, alerts, or other information disseminated by the FDA as applicable); (ii) research of current medical and pharmacy literature; and/or (iii) review of common medical practices in the treatment and diagnosis of disease as of the date hereof. Physicians and other providers are solely responsible for all aspects of medical care and treatment, including the type, quality, and levels of care and treatment.
The purpose of Blue Cross and Blue Shield of Alabama’s pharmacy policies are to provide a guide to coverage. Pharmacy policies are not intended to dictate to physicians how to practice medicine. Physicians should exercise their medical judgment in providing the care they feel is most appropriate for their patients.
Neither this policy, nor the successful adjudication of a pharmacy claim, is guarantee of payment.
ALBP_PS_ACA_Copay_Waiver_Breast_Cancer_Prevention_ProgSum_01-01-2024